As an update to the communication issued on August 3, 2023 regarding the ongoing national shortage of Dipyridamole for Injection in Canada, Health Canada wishes to advise that new Canadian supply is now available from Fresenius Kabi Canada. This supply will be allocated to historical Fresenius Kabi Canada customers and a portion of Glenwood customers.
Hikma Canada has also imported additional US-authorized Dipyridamole Injection, USP in September 2023 to support any remaining supply gaps as needed.
Overall supply is expected to be sufficient to cover full market demands moving forward. As such, no further extensions will be made for the shelf-life of the 9 lots of Persantine from Glenwood with labelled expiry of June 30, 2023. This shortage will continue to be monitored until Canadian supply becomes more stable.